CD24 Polymorphisms Cannot Predict Pathologic Complete Response to Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy in Breast Cancer

CD24 rs3838646 and rs52812045 polymorphism could not predict the pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer. Additional larger studies are required to confirm this finding.